Ad
Sunday, 24 February 2019
Novartis licenses rights to RNA-targeting cardio drug from Ionis
Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational, RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment